During the radiotherapy treatment of patients with lung cancer, the radiation delivered to healthy tissue around the tumor needs to be minimized, which is difficult because of respiratory motion and the latency of linear accelerator (LINAC) systems. In the proposed study, we first use the Lucas-Kanade pyramidal optical flow algorithm to perform deformable image registration (DIR) of chest computed tomography (CT) scan images of four patients with lung cancer. We then track three internal points close to the lung tumor based on the previously computed deformation field and predict their position with a recurrent neural network (RNN) trained using real-time recurrent learning (RTRL) and gradient clipping. The breathing data is quite regular, sampled at approximately 2.5 Hz, and includes artificially added drift in the spine direction. The amplitude of the motion of the tracked points ranged from 12.0 mm to 22.7 mm. Finally, we propose a simple method for recovering and predicting three-dimensional (3D) tumor images from the tracked points and the initial tumor image, based on a linear correspondence model and the Nadaraya-Watson non-linear regression. The root-mean-square (RMS) error, maximum error and jitter corresponding to the RNN prediction on the test set were smaller than the same performance measures obtained with linear prediction and least mean squares (LMS). In particular, the maximum prediction error associated with the RNN, equal to 1.51 mm, is respectively 16.1% and 5.0% lower than the error given by a linear predictor and LMS. The average prediction time per time step with RTRL is equal to 119 ms, which is less than the 400 ms marker position sampling time. The tumor position in the predicted images appears visually correct, which is confirmed by the high mean cross-correlation between the original and predicted images, equal to 0.955. The standard deviation of the Gaussian kernel and the number of layers in the optical flow algorithm were the parameters having the most significant impact on registration performance. Their optimization led respectively to a 31.3% and 36.2% decrease in the registration error. Using only a single layer proved to be detrimental to the registration quality because tissue motion in the lower part of the lung has a high amplitude relative to the resolution of the CT scan images. The random initialization of the hidden units and the number of these hidden units were found to be the most important factors affecting the performance of the RNN. Increasing the number of hidden units from 15 to 250 led to a 56.3% decrease in the prediction error on the cross-validation data. Similarly, optimizing the standard deviation of the initial Gaussian distribution of the synaptic weights σ led to a 28.4% decrease in the prediction error on the cross-validation data, with the error minimized for σ=0.02 with the four patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compmedimag.2021.101941DOI Listing

Publication Analysis

Top Keywords

lung cancer
12
prediction error
12
hidden units
12
internal points
8
recurrent neural
8
neural network
8
trained real-time
8
real-time recurrent
8
recurrent learning
8
patients lung
8

Similar Publications

Pulmonary embolism (PE), a form of venous thromboembolism, is a frequently observed complication in malignancies, with a notably high incidence in individuals with lung cancer. The presence of PE markedly reduces the quality of life and has a significant impact on the prognosis of those diagnosed with both lung cancer and PE. As a result, timely diagnosis and intervention are of paramount importance.

View Article and Find Full Text PDF

Evaluation of an enhanced ResNet-18 classification model for rapid On-site diagnosis in respiratory cytology.

BMC Cancer

January 2025

Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.

Objective: Rapid on-site evaluation (ROSE) of respiratory cytology specimens is a critical technique for accurate and timely diagnosis of lung cancer. However, in China, limited familiarity with the Diff-Quik staining method and a shortage of trained cytopathologists hamper utilization of ROSE. Therefore, developing an improved deep learning model to assist clinicians in promptly and accurately evaluating Diff-Quik stained cytology samples during ROSE has important clinical value.

View Article and Find Full Text PDF

Background: With extended gefitinib treatment, the therapeutic effect in some non-small cell lung cancer (NSCLC) patients declined with the development of drug resistance. Aidi injection (ADI) is utilized in various cancers as a traditional Chinese medicine prescription. This study explores the molecular mechanism by which ADI, when combined with gefitinib, attenuates gefitinib resistance in PC9GR NSCLC cells.

View Article and Find Full Text PDF

Background: To date, there remains a paucity of comparative investigations pertaining to preoperative immunochemotherapy and conventional chemotherapy in the context of limited-stage small-cell lung cancer (LS-SCLC) patients. This study conducted a comprehensive comparative assessment concerning the safety and efficacy profiles of preoperative immunochemotherapy and chemotherapy in individuals diagnosed with stage I-IIIB SCLC.

Methods: This investigation collected 53 consecutive patients diagnosed with LS-SCLC spanning stage I to IIIB who underwent preoperative immunochemotherapy or conventional chemotherapy at our hospital from January 2019 to July 2021.

View Article and Find Full Text PDF

Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy.

Acta Pharmacol Sin

January 2025

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, 300350, China.

Histone lysine-specific demethylase 1 (LSD1) is overexpressed in various solid and hematological tumors, suggesting its potential as a therapeutic target, but there are currently no LSD1 inhibitors available on the market. In this study we employed a computer-guided approach to identify novel LSD1/EGFR dual inhibitors as a potential therapeutic agent for non-small cell lung cancer. Through a multi-stage virtual screening approach, we found L-1 and L-6, two compounds with unique scaffolds that effectively inhibit LSD1 with IC values of 6.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!